GO:0005130 granulocyte colony-stimulating factor receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005130 describes the molecular function of binding to the granulocyte colony-stimulating factor receptor (G-CSFR), a cytokine receptor encoded by CSF3R.
• G-CSF binding to G-CSFR triggers receptor dimerization and activation of JAK/STAT, MAPK, and PI3K signaling pathways that drive granulopoiesis.
• Mutations in CSF3R are linked to severe congenital neutropenia, chronic neutrophilic leukemia, and other myeloid malignancies.
• The ligand-binding domain of G-CSFR has been mapped to specific extracellular regions, and C-mannosylation regulates receptor-mediated granulocytic differentiation.
• G-CSFR expression varies across differentiation stages of normal and leukemic hematopoietic cells, making it a useful marker and therapeutic target.
• Engineered anti-G-CSFR nanobodies with improved affinity are being developed as research tools and potential therapeutics.
Description
Granulocyte colony-stimulating factor receptor binding (GO:0005130) is a molecular function that describes the physical interaction between a ligand and the granulocyte colony-stimulating factor receptor (G-CSFR). This receptor, encoded by the CSF3R gene, is a member of the cytokine receptor superfamily and plays a central role in the production, differentiation, and function of neutrophils. The binding event is the first step in a signaling cascade that ultimately controls granulopoiesis under steady-state and stress conditions. Understanding this function is critical for researchers studying hematopoiesis, innate immunity, and myeloid malignancies. The G-CSF/G-CSFR axis is clinically important because mutations in CSF3R are associated with severe congenital neutropenia and leukemias, and recombinant G-CSF is widely used to treat neutropenia. Moreover, the receptor's expression pattern changes during hematopoietic differentiation, making it a valuable marker for studying normal and leukemic cell development. This article provides a comprehensive overview of the biological process, cellular components, and molecular mechanisms underlying GO:0005130, along with key genes, disease associations, and research methods including CRISPR-based models.
granulocyte colony-stimulating factor receptor binding At A Glance
| GO ID | GO:0005130 |
|---|---|
| GO term | granulocyte colony-stimulating factor receptor binding |
| Ontology | molecular_function |
| Synonym | G-CSF receptor ligand; GC-SF receptor ligand; granulocyte colony-stimulating factor; granulocyte colony stimulating factor receptor binding; granulocyte colony-stimulating factor receptor ligand |
| Major function | Binding to the granulocyte colony-stimulating factor receptor, initiating signaling for granulopoiesis |
| Related gene | CSF3R (G-CSFR), CSF3 (G-CSF) |
| Associated diseases | Severe congenital neutropenia, chronic neutrophilic leukemia, myeloproliferative neoplasms |
| Research relevance | Target for neutropenia treatment, leukemia studies, and hematopoietic differentiation research |
What Is GO:0005130?
According to the Gene Ontology, GO:0005130 (granulocyte colony-stimulating factor receptor binding) is defined as the binding to a granulocyte colony-stimulating factor receptor. This molecular function encompasses the selective interaction between a ligand (such as G-CSF) and the G-CSFR, leading to receptor activation. It is a ligand-receptor binding event that initiates intracellular signaling.
Why Is granulocyte colony-stimulating factor receptor binding Important in Cell Biology?
GO:0005130 is essential because it represents the initial molecular event that controls neutrophil production and function. Dysregulation of this binding function leads to severe hematological disorders, including severe congenital neutropenia and myeloid malignancies. Understanding the precise binding mechanism informs the development of therapeutic agents, such as modified G-CSF variants or anti-G-CSFR nanobodies, and provides insights into how mutations in CSF3R alter receptor function.
• Controls granulopoiesis and neutrophil homeostasis.
• Mutations in CSF3R cause severe congenital neutropenia and predispose to leukemia.
• CSF3R mutations are found in chronic neutrophilic leukemia and atypical chronic myeloid leukemia.
• G-CSFR expression is a marker for myeloid differentiation stages.
• C-mannosylation of G-CSFR regulates its function in granulocytic differentiation.
• Ligand-binding domain mapping aids in understanding receptor activation.
• Engineered nanobodies against G-CSFR offer research and therapeutic potential.
• The G-CSF/G-CSFR axis is a target for treating neutropenia and myeloid disorders.
Molecular Function of granulocyte colony-stimulating factor receptor binding
Ligand Recognition and Binding
In simple terms: G-CSF grabs onto its receptor like a key fitting a lock.
The binding of granulocyte colony-stimulating factor (G-CSF) to its receptor (G-CSFR) is a high-affinity interaction that occurs at the extracellular domain of the receptor. The ligand-binding domain of G-CSFR has been mapped to specific regions, and this binding is the first step in receptor activation. This interaction is highly specific, ensuring that G-CSF signals through its cognate receptor.
Receptor Dimerization and Activation
In simple terms: Once the key is in the lock, two receptors pair up to send a signal inside the cell.
Upon G-CSF binding, G-CSFR undergoes conformational changes that lead to receptor dimerization. This dimerization activates associated JAK kinases, which then phosphorylate the receptor and downstream signaling molecules. This activation is critical for transmitting the signal into the cell.
Post-translational Modification: C-mannosylation
In simple terms: A sugar tag on the receptor helps it work properly.
C-mannosylation of G-CSFR is a post-translational modification that regulates receptor-mediated granulocytic differentiation. This modification occurs in the extracellular domain and influences receptor function and stability.
Signaling Downstream of G-CSFR
In simple terms: The signal travels through several pathways to tell the cell to make neutrophils.
Activated G-CSFR triggers multiple signaling cascades, including JAK/STAT, MAPK/ERK, and PI3K/AKT pathways. These pathways collectively regulate gene expression, cell proliferation, and differentiation toward neutrophils.
Key Genes Involved in GO:0005130 granulocyte colony-stimulating factor receptor binding
The following genes and proteins are directly involved in or regulate granulocyte colony-stimulating factor receptor binding and its downstream effects.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CSF3R | Encodes the G-CSF receptor; binds G-CSF | Mutations linked to neutropenia and leukemia |
| CSF3 | Encodes G-CSF, the ligand that binds G-CSFR | Therapeutic use in neutropenia; binding studies |
| JAK2 | Kinase activated by G-CSFR dimerization | Mutations in myeloproliferative neoplasms |
| STAT3 | Transcription factor downstream of G-CSFR | Mediates granulopoiesis and survival signals |
| STAT5 | Transcription factor downstream of G-CSFR | Regulates proliferation and differentiation |
| LYN | Src-family kinase involved in G-CSFR signaling | Modulates receptor activation |
| SHP2 (PTPN11) | Phosphatase that regulates G-CSFR signaling | Mutations in leukemias |
| SOCS3 | Negative regulator of G-CSFR signaling | Feedback inhibition of cytokine signaling |
| CBL | E3 ubiquitin ligase that downregulates G-CSFR | Receptor internalization and degradation |
| GRB2 | Adaptor protein in MAPK pathway | Links G-CSFR to Ras/MAPK |
| PIK3CA | Catalytic subunit of PI3K | PI3K/AKT pathway activation |
| AKT1 | Serine/threonine kinase | Survival signaling downstream of G-CSFR |
| MAPK1 (ERK2) | Kinase in MAPK cascade | Proliferation and differentiation |
| ELANE | Neutrophil elastase | Mutations in severe congenital neutropenia |
| HAX1 | HS1-associated protein X-1 | Mutations in severe congenital neutropenia |
| G6PC3 | Glucose-6-phosphatase catalytic subunit 3 | Mutations in severe congenital neutropenia |
| GFI1 | Transcription repressor | Mutations in severe congenital neutropenia |
| WAS | Wiskott-Aldrich syndrome protein | Mutations in severe congenital neutropenia |
How Is granulocyte colony-stimulating factor receptor binding Regulated?
The binding of G-CSF to G-CSFR and subsequent signaling are tightly regulated at multiple levels. Negative feedback mechanisms involve SOCS proteins, which are induced by cytokine signaling and inhibit JAK/STAT pathways. Receptor internalization and degradation are mediated by ubiquitination, involving E3 ligases such as CBL. Additionally, post-translational modifications like C-mannosylation can modulate receptor function. Dysregulation of these control mechanisms contributes to leukemogenesis and other hematopoietic disorders.
granulocyte colony-stimulating factor receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CSF3R | Severe congenital neutropenia; chronic neutrophilic leukemia | Knock-in of patient mutations in hematopoietic stem cells |
| CSF3R | Ligand-independent activation in leukemia | Point mutation (e.g., T618I) knock-in in cell lines |
| ELANE | Severe congenital neutropenia | Knockout or point mutation in iPSCs |
| JAK2 | Myeloproliferative neoplasms | Knock-in of V617F mutation |
| STAT3 | Hyper-IgE syndrome; immune dysregulation | Knockout in hematopoietic cells |
Severe Congenital Neutropenia (SCN)
Severe congenital neutropenia is a group of disorders characterized by a severe reduction in neutrophil counts. Mutations in CSF3R, particularly those affecting the extracellular domain, can impair G-CSF binding and signaling, leading to neutropenia. Patients with SCN often have mutations in ELANE, HAX1, G6PC3, GFI1, or WAS, and some acquire CSF3R mutations that predispose to leukemia.
Myeloid Malignancies
Mutations in CSF3R are found in chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML). These mutations often affect the extracellular domain or the transmembrane domain, leading to ligand-independent activation of the receptor. Such mutations drive constitutive signaling and contribute to leukemic transformation.
Myeloproliferative Neoplasms
Classical myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, are driven by mutations in JAK2, CALR, or MPL. Although CSF3R mutations are less common, dysregulated G-CSF signaling can contribute to the pathophysiology of these diseases.
From granulocyte colony-stimulating factor receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a CSF3R mutation cause ligand-independent activation? | Point mutation knock-in (e.g., T618I) in myeloid cell lines |
| What is the role of C-mannosylation in G-CSFR function? | Knockout of mannosyltransferase in hematopoietic cells |
| How does G-CSFR expression change during differentiation? | Tagged knock-in of fluorescent reporter at CSF3R locus |
| Can a candidate gene regulate G-CSFR signaling? | CRISPR knockout screen in G-CSF-responsive cells |
| Does overexpression of G-CSFR enhance granulopoiesis? | Overexpression of CSF3R in hematopoietic progenitors |
| What are the off-target effects of anti-G-CSFR nanobodies? | Knock-in of epitope tags for binding assays |
How to Study the granulocyte colony-stimulating factor receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance (SPR) | Binding affinity and kinetics | Characterizing G-CSF/G-CSFR interaction |
| Western blot | Protein phosphorylation and expression | Assessing JAK/STAT activation |
| Flow cytometry | Cell surface receptor expression | Monitoring differentiation stages |
| CRISPR knockout screen | Gene essentiality for G-CSFR signaling | Identifying novel regulators |
| RNA-seq | Transcriptional changes upon G-CSF stimulation | Global gene expression profiling |
| Proteomics | Protein-protein interactions and post-translational modifications | Mapping signaling complexes |
| Immunoprecipitation | Physical interactions | Detecting receptor-associated proteins |
Binding Assays
Surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) can measure the binding affinity between G-CSF and G-CSFR. These methods provide kinetic and thermodynamic parameters essential for understanding the molecular function.
Signaling Pathway Analysis
Western blotting and phospho-proteomics can assess activation of JAK/STAT, MAPK, and PI3K pathways upon G-CSF stimulation. These techniques reveal downstream effects of receptor binding.
CRISPR Screening
Genome-wide CRISPR knockout screens can identify genes that regulate G-CSFR expression or signaling. Such screens are powerful for discovering novel modulators of granulopoiesis.
Flow Cytometry
Flow cytometry using fluorescently labeled G-CSF or anti-G-CSFR antibodies can quantify receptor expression and binding at the single-cell level, useful for studying differentiation stages.
How CRISPR Can Be Used to Study GO:0005130 granulocyte colony-stimulating factor receptor binding
Knockout
CRISPR knockout of CSF3R or downstream signaling genes (e.g., JAK2, STAT3) can abolish G-CSF responsiveness, providing a clean system to study the necessity of these components in granulopoiesis.
Point Mutation
Introducing patient-specific point mutations (e.g., CSF3R T618I) via CRISPR base editing or homology-directed repair allows researchers to model ligand-independent activation and study leukemogenesis.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA) or fluorescent reporters at the endogenous CSF3R locus enables tracking of receptor expression, localization, and interaction partners in live cells.
Overexpression
Overexpression of wild-type or mutant CSF3R in hematopoietic cell lines can enhance signaling and drive differentiation or transformation, useful for gain-of-function studies.
How EDITGENE Supports granulocyte colony-stimulating factor receptor binding Research
Researchers studying granulocyte colony-stimulating factor receptor binding-related genes often need to determine whether a candidate gene is causally involved in receptor function, signaling, or disease. EDITGENE provides a comprehensive suite of CRISPR services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for granulocyte colony-stimulating factor receptor binding research.
Frequently Asked Questions About granulocyte colony-stimulating factor receptor binding
What is granulocyte colony-stimulating factor receptor binding?
It is a molecular function (GO:0005130) where a ligand binds to the G-CSF receptor, initiating signaling for neutrophil production.
What genes are involved in granulocyte colony-stimulating factor receptor binding?
Key genes include CSF3R (encoding the receptor), CSF3 (encoding the ligand), and downstream signaling genes like JAK2, STAT3, and STAT5.
What diseases are associated with G-CSFR binding defects?
Mutations in CSF3R are linked to severe congenital neutropenia, chronic neutrophilic leukemia, and other myeloid malignancies.
How is G-CSFR binding studied in the lab?
Common methods include surface plasmon resonance, flow cytometry, Western blotting, and CRISPR screens.
What is the role of C-mannosylation in G-CSFR function?
C-mannosylation is a post-translational modification that regulates G-CSFR-mediated granulocytic differentiation.
Can CRISPR be used to model G-CSFR mutations?
Yes, CRISPR knockout, point mutation knock-in, and overexpression models are widely used to study G-CSFR function and disease.
What is the ligand-binding domain of G-CSFR?
The ligand-binding domain is located in the extracellular region of the receptor and is responsible for specific G-CSF binding.
How does G-CSFR expression change during differentiation?
G-CSFR expression varies across differentiation stages of normal and leukemic hematopoietic cells, serving as a differentiation marker.
What are anti-G-CSFR nanobodies?
Engineered nanobodies with improved affinity for G-CSFR are being developed as research tools and potential therapeutics.
What signaling pathways are activated by G-CSFR binding?
JAK/STAT, MAPK/ERK, and PI3K/AKT pathways are major downstream cascades activated by G-CSFR.
Conclusion
Granulocyte colony-stimulating factor receptor binding (GO:0005130) is a fundamental molecular function that governs neutrophil development and function. Its dysregulation is central to severe congenital neutropenia and myeloid leukemias, making it a critical area of research. Advances in CRISPR-based models and screening technologies continue to unravel the complexities of G-CSFR signaling, offering new avenues for therapeutic intervention. EDITGENE's comprehensive services support researchers in dissecting this pathway with precision and scale.
References
- 1. Skokowa J et al.. 2017. Severe congenital neutropenias.. Nat Rev Dis Primers 3:17032 PMID: 28593997
- 2. Bakherad H et al.. 2020. Engineering an anti-granulocyte colony stimulating factor receptor nanobody for improved affinity.. Life Sci 257:118052 PMID: 32634431
- 3. Vainchenker W et al.. 2017. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.. Blood 129(6):667-679 PMID: 28028029
- 4. Dwivedi P et al.. 2017. Granulocyte colony-stimulating factor receptor signaling in severe congenital neutropenia, chronic neutrophilic leukemia, and related malignancies.. Exp Hematol 46:9-20 PMID: 27789332
- 5. Otani K et al.. 2018. Regulation of granulocyte colony-stimulating factor receptor-mediated granulocytic differentiation by C-mannosylation.. Biochem Biophys Res Commun 498(3):466-472 PMID: 29501745
- 6. Shinjo K et al.. 1997. Granulocyte colony-stimulating factor receptor at various differentiation stages of normal and leukemic hematopoietic cells.. Leuk Lymphoma 25(1-2):37-46 PMID: 9130612
- 7. Hiraoka O et al.. 1994. Ligand binding domain of granulocyte colony-stimulating factor receptor.. J Biol Chem 269(35):22412-9 PMID: 7520915
- 8. Xing Y et al.. 2016. Colony Stimulating Factor 3 Mutations and Myeloid Malignancies.. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 38(1):103-7 PMID: 26956865
